Indian company launches drug to treat mild, moderate Covid-19 patients; another gunfight breaks out in Kashmir

  • 📰 staronline
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 75%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

MUMBAI (Xinhua): Glenmark Pharmaceuticals has become the first Indian company to launch anti-viral drug Favipiravir for the treatment of mild to moderate Covid-19 patients in the domestic market following the manufacturing approval from the drug regulator, a company statement said.

Launched under the brand name FabiFlu, the oral drug will be available as a prescription-based medication for US$1.35 per tablet.

It offers rapid reduction in viral load within four days and has shown clinical improvement of up to 88 per cent in mild to moderate Covid-19 cases, it added. In another development, a gunfight between militants and government forces broke out Sunday in restive Indian-controlled Kashmir, police said."A gunfight started between militants and joint contingents of police and paramilitary at Zadibal-Soura area of the city early today," a police spokesman said."The stand-off is underway."

 

コメントありがとうございます。コメントは審査後に公開されます。
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 4. in JP

日本 最新ニュース, 日本 見出し